Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. The company was founded in 2002 and is based in Cambridge, Massachusetts.

Acquired Companies: Ribopharma AG